In conclusion, our data indicate that low CD21 expression on CLL cells is intrinsically a marker of poor prognosis in the disease and support the growing evidence that BCR cell signaling pathways play a key role in modulating the clinical course of this disease. This evidence concerns the gene CR2 and B-cell chronic lymphocytic leukemia.